Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

2013; Elsevier BV; Volume: 122; Issue: 15 Linguagem: Inglês

10.1182/blood-2013-06-507947

ISSN

1528-0020

Autores

Jason A. Dubovsky, Kyle A. Beckwith, Gayathri Natarajan, Jennifer A. Woyach, Samantha Jaglowski, Yiming Zhong, Joshua Hessler, Ta-Ming Liu, Betty Chang, Karilyn M. Larkin, Matthew Stefanovski, Danielle L. Chappell, Frank Frissora, Lisa L. Smith, Kelly A. Smucker, Joseph M. Flynn, Jeffrey A. Jones, Leslie A. Andritsos, Kami J. Maddocks, Amy M. Lehman, Richard R. Furman, Jeff P. Sharman, Anjali Mishra, Michael A. Caligiuri, Abhay R. Satoskar, Joseph J. Buggy, Natarajan Muthusamy, Amy J. Johnson, John C. Byrd,

Tópico(s)

Immunodeficiency and Autoimmune Disorders

Resumo

Key Points Ibrutinib is the first clinically viable irreversible ITK inhibitor. Ibrutinib inhibits the formation of Th2 but not Th1 immunity.

Referência(s)